Diese Webseite nutzt Cookies zur Verbesserung des Erlebnisses unserer Besucher. Indem Sie weiterhin auf dieser Webseite navigieren, erklären Sie sich mit unserer Verwendung von Cookies einverstanden.
A New Generation of Targeted Diagnostic and Therapeutic Radiopharmaceuticals & Radioisotopes
We offer radioisotopes for clinical applications as well as research purposes. We have therefore established a GMP manufacturing of a first-in-class radioisotopes and -generator platform for the development of a new generation of targeted cancer diagnostics and therapies.
In 2016, we received Marketing Authorization for EndolucinBeta®. EndolucinBeta® respectively no-carrier-added (n.c.a.) lutetium (177Lu) chloride is a radiopharmaceutical precursor and indicated for the radiolabeling of disease-specific carrier molecules. The emerging radiopharmaceutical can be applied in Targeted Radionuclide Therapy for cancer treatment.
Get in touch with our Sales Team
If you are in need of any further information regarding radioisotopes or radiopharmaceuticals and our worldwide service, please contact us:
